No black box warning on record for Carvedilol Phosphate

As of the latest FDA labeling reviewed, Carvedilol Phosphate (CARVEDILOL PHOSPHATE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Carvedilol Phosphate medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS In clinical trials of extended-release carvedilol phosphate capsules in subjects with hypertension (338 subjects) and in subjects with left ventricular dysfunction following a myocardial infarction or heart failure (187 subjects), the profile of adverse events observed with carvedilol phosphate was generally similar to that observed with the administration of immediate-r

No black box warning on record for Carvedilol Phosphate

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS In clinical trials of extended-release carvedilol phosphate capsules in subjects with hypertension (338 subjects) and in subjects with left ventricular dysfunction following a myocardial infarction or heart failure (187 subjects), the profile of adverse events observed with carvedilol phosphate was generally similar to that observed with the administration of immediate-r

Carvedilol Phosphate Black Box Warning

No black box warning on record for Carvedilol Phosphate

Other warnings & precautions

Carvedilol Phosphate Black Box Warning

No black box warning on record for Carvedilol Phosphate

Other warnings & precautions